Analyst Research

Report Title Price
Provider : Thomson Reuters Stock Report
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc and Theravance Inc announce Anoro (Umeclidinium/Vilanterol) gains marketing authorisation in Europe for the treatment of COPD

Thursday, 8 May 2014 11:12am EDT 

Glaxosmithkline Plc and Theravance Inc:Says the European Commission has granted marketing authorisation for Anoro (umeclidinium/vilanterol) as a once-daily, maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment to GSK of $15 mln following marketing authorisation for UMEC/VI by the European Commission.A further $15 mln payment to GSK will follow the launch of UMEC/VI in Europe.First launch is expected to take place in Europe in Q2-3 2014 with additional launches to follow thereafter. 

Company Quote

-0.11 -1.26%
9 Oct 2015